What is Rivus Pharmaceuticals?
Rivus Pharmaceuticals is a clinical-stage biotechnology firm specializing in the field of mitochondrial biology. The company is pioneering a novel class of medicines known as Controlled Metabolic Accelerators (CMAs). These therapeutics are designed to harness the natural process of mitochondrial uncoupling, providing a measured and physiological approach to reducing excess body fat. By targeting the root drivers of cardio-metabolic disease, Rivus aims to provide transformative treatment options for patients suffering from obesity and its associated health complications. The company's market position is defined by its scientific rigor and its potential to disrupt the current landscape of metabolic disease management.
How much funding has Rivus Pharmaceuticals raised?
Rivus Pharmaceuticals has raised a total of $187M across 2 funding rounds:
Series A
$55M
Series B
$132M
Series A (2021): $55M with participation from Longitude Capital, Medicxi, and Rx Capital Group
Series B (2022): $132M led by RA Capital Management, Medicxi, Longitude Capital, BB Biotech Ventures, and Bain Capital
Key Investors in Rivus Pharmaceuticals
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its internal TechAtlas think tank to support clinical development.
Medicxi
Medicxi is a specialized healthcare investment firm that provides financial resources and strategic guidance to early-to-mid-stage biotechnology companies to enhance patient outcomes.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that pairs sector expertise and flexible capital to help biotechnology and medical technology innovators scale their operations.
What's next for Rivus Pharmaceuticals?
With the infusion of capital from its latest financing round, Rivus Pharmaceuticals is well-positioned to advance its clinical development programs. The strategic focus will likely center on moving its lead CMA candidates through critical human trials, gathering the necessary data to validate the safety and efficacy of its mitochondrial uncoupling platform. As the company transitions from early-stage research to more advanced clinical milestones, it will continue to refine its therapeutic delivery mechanisms. The firm's ability to maintain strong relationships with its syndicate of healthcare-focused investors will be instrumental in navigating the complex regulatory and commercial pathways required to bring these innovative treatments to market, ultimately aiming to improve long-term health outcomes for millions of patients globally.
See full Rivus Pharmaceuticals company page
